Metabolic profile of puerarin in rats after intragastric administration of puerarin solid lipid nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 933-940

  Luo, Cheng Feng ^a,b   Hou, Ning ^a,b   Tian, Juan ^a,b   Yuan, Mu ^a,b   Liu, Shi Ming ^a,b   Xiong, Long Gen ^a,b   Luo, Jian Dong ^a,b   Chen, Min Sheng ^a,b,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Guangzhou Institute of Cardiovascular Disease   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Metabolic profiling; Puerarin; Solid lipid nanoparticles

Indexed keywords

DRUG METABOLITE; PUERARIN; PUERARIN 4' O GLUCURONIDE; PUERARIN 7 O GLUCURONIDE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG URINE LEVEL; EXPERIMENTAL RAT; FEMALE; GLUCURONIDATION; MALE; METABOLITE; NONHUMAN; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84874857868     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39349     Document Type: Article

References (25)

1. Song XP, Chen PP, Chai XS. Effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats. Zhongguo Yao Li Xue Bao. 1988;9(1):55-58. Chinese.
2. Gao L, Ji X, Song J, et al. Puerarin protects against ischemic brain injury in a rat model of transient focal ischemia. Neurol Res. 2009;31(4): 402-406.
3. Zhang S, Chen S, Shen Y, et al. Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol Pharm Bull. 2006;29(5):945-950.
4. Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod. 2003;66(6):788-792.
5. Xu ME, Xiao SZ, Sun YH, Zheng XX, Ou-Yang Y, Guan C. The study of anti-metabolic syndrome effect of puerarin in vitro. Life Sci. 2005;77(25):3183-3196.
6. Yan LP, Chan SW, Chan AS, Chen SL, Ma XJ, Xu HX. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci. 2006;79(4):324-330.
7. Han RM, Tian YX, Becker EM, Andersen ML, Zhang JP, Skibsted LH. Puerarin and conjugate bases as radical scavengers and antioxidants: Molecular mechanism and synergism with beta-carotene. J Agric Food Chem. 2007;55(6):2384-2391.
8. Hu W, Zhang Q, Yang X, Wang Y, Sun L. Puerarin inhibits adhesion molecule expression in TNF-alpha-stimulated human endothelial cells via modulation of the nuclear factor kappaB pathway. Pharmacology. 2010;85(1):27-35.
9. Yang X, Hu W, Zhang Q, Wang Y, Sun L. Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol. 2010;107(2):637-642.
10. Hwang YP, Kim HG, Hien TT, Jeong MH, Jeong TC, Jeong HG. Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol Appl Pharmacol. 2011;257(1):48-58.
11. Malaivijitnond S, Tungmunnithum D, Gittarasanee S, Kawin K, Limjunyawong N. Puerarin exhibits weak estrogenic activity in female rats. Fitoterapia. 2010;81(6):569-576.
12. Prasain JK, Jones K, Brissie N, Moore R, Wyss JM, Barnes S. Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry. J Agric Food Chem. 2004; 52(12):3708-3712.
13. Prasain JK, Peng N, Moore R, Arabshahi A, Barnes S, Wyss JM. Tissue distribution of puerarin and its conjugated metabolites in rats assessed by liquid chromatography-tandem mass spectrometry. Phytomedicine. 2009;16(1):65-71.
14. Yasuda T, Kano Y, Saito K, Ohsawa K. Urinary and biliary metabolites of puerarin in rats. Biol Pharm Bull. 1995;18(2):300-303.
15. Luo CF, Cai B, Hou N, et al. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes. Arch Toxicol. 2012;86(11):1681-1690.
16. Luo CF, Yuan M, Chen MS, Liu SM, Ji H. Metabolites of puerarin identified by liquid chromatography tandem mass spectrometry: similar metabolic profiles in liver and intestine of rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(3-4):363-370.
17. Quan DQ, Xu GX, Wu XG. Studies on preparation and absolute bioavailability of a self-emulsifying system containing puerarin. Chem Pharm Bull (Tokyo). 2007;55(5):800-803.
18. Luo CF, Yuan M, Chen MS, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm. 2011;410(1-2):138-144.
19. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008;34(12):1394-1405.
20. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 2009;5(2):184-191.
21. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581-616.
22. Chen J, Wang S, Jia X, et al. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005;33(12):1777-1784.
23. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993;342(8881): 1209-1210.
24. Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, et al. Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci. 2009;109(2):257-264.
25. Galindo P, Rodriguez-Gómez I, González-Manzano S, et al. Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation. PLoS One. 2012;7(3):e32673.